HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Torrent Pharmaceuticals Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Torrent Pharmaceuticals Intelligence Report

Generated from 6 signals · 5 evidence sources

Type

Company Intelligence Report

Generated

Jul 25, 2026

Confidence

Moderate Confidence · 69%

Evidence

23 items

Sources

15

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Torrent Pharmaceuticals maintains an active intelligence profile across Infectious Disease, Antibiotic, Diabetes, Oral Hypoglycemic, Cardiology. 6 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 69% across 5 tracked sources. Highest-priority development: Lurasidone Hydrochloride. Portfolio development. Lurasidone Hydrochloride is an owned Torrent Pharmaceuticals portfolio development in Psychiatry · Antipsychotic.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA AP — BUPRENORPHINE HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA AP — TRAMADOL HYDROCHLORIDE (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    FDA AP — PITOLISANT HYDROCHLORIDE (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA AP — DOXEPIN HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA AP — DOXEPIN HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA AP — BAXFENDY (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — BAXFENDY (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA TA — VERICIGUAT (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 223 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — BUPRENORPHINE HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — TRAMADOL HYDROCHLORIDE (ORIG)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — PITOLISANT HYDROCHLORIDE (ORIG)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — DOXEPIN HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — DOXEPIN HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BAXFENDY (ORIG)

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — BAXFENDY (ORIG)

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Low Confidence · 54%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA TA — VERICIGUAT (ORIG)

    Low Confidence · 54%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 77%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Lurasidone Hydrochloride

    Moderate Confidence · 78%

    Portfolio asset at Approved stage

    Source: AutoResearch, Competitiva, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Torrent Pharmaceuticals submits ANDA for Vericiguat

    Cardiology · Heart Failure

  • Torrent's Moxifloxacin Hydrochloride ANDA Receives Approval Status

    Infectious Disease · Antibiotic

  • Torrent's Metformin Hydrochloride ANDA090014 Receives AP Status

    Diabetes · Oral Hypoglycemic

  • Torrent's Lurasidone Hydrochloride ANDA Receives AP Status from FDA

    Psychiatry · Antipsychotic

  • Torrent Pharmaceuticals receives AP status for Metformin Hydrochloride ANDA079226

    Diabetes · Oral Hypoglycemic

  • Torrent Pharmaceuticals receives AP status for Metformin Hydrochloride ANDA077711

    Diabetes · Oral Hypoglycemic

Assets

  • Lurasidone Hydrochloride

    Portfolio asset

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.